This systematic review aims to evaluate the current clinical evidence regarding the association between body composition, specifically BMI, pretreatment weight loss sarcopenia and cachexia, and the clinical outcomes in NSCLC patients treated with PD-1 or PD-L1 inhibitors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.